Results 161 to 170 of about 28,261 (176)

VSV-EBOV Rapidly Protects Macaques Against Infection With the 2014/15 Ebola Virus Outbreak Strain

Science, 2015
This study analyzed how many days between vaccination with VSV-EBOV and lethal EBOV challenge are needed for protection in macaques. Results showed that 7 days as a minimum between vaccination and challenge offered 100% protection. The study is published
Heinz Feldmann, James E Strong, Friederike Feldmann   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.

Journal of Infectious Diseases, 2023
Heinz Feldmann, Armand Sprecher, Andrea Marzi   +2 more
exaly  

VSV-EBOV Induces Temporal and Dose-Dependent Transcriptional Responses in Non-Human Primates

Frontiers in Virology, 2021
Andrea Marzi, Ilhem Messaoudi, Amanda N Pinski   +2 more
exaly  

RNA Secondary Structure at the Transcription Start Site Influences EBOV Transcription Initiation and Replication in a Length- and Stability-Dependent Manner

RNA Biology, 2021
Roland K Hartmann, Jana-Christin Demper, Stephan Becker   +2 more
exaly  

Intradermal Immunization of EBOV VLPs in Guinea Pigs Induces Broader Antibody Responses Against GP Than Intramuscular Injection

Frontiers in Microbiology, 2020
Ricardo Carrion, Jean L. Patterson, Chinglai Yang   +2 more
exaly  

Development and Evaluation of a Real-Time EBOV-L-RT-qPCR for Detection of Zaire Ebolavirus

Journal of Clinical Virology, 2015
Kirsi Aaltonen, Tarja Sironen, Olli Vapalahti   +2 more
exaly  

Usp18 Expression in CD169+ Macrophages Is Important for Strong Immune Response After Vaccination With VSV-EBOV

Vaccines, 2020
Judith Lang, Kenichi Asano, Marco Prinz
exaly  

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection.

MBio, 2019
Ilhem Messaoudi, Heinz Feldmann, Andrea Marzi   +2 more
exaly  

Dynamic Changes of Circulating miRNAs Induced by the Ebola Virus Vaccine VSV-EBOV

Vaccine, 2018
S Schmiedel
exaly  

Open-Label Phase I Clinical Trial of Ad5-EBOV in Africans in China

Human Vaccines and Immunotherapeutics, 2017
Nanping Wu, Pei Liu, Hang-Ping Yao
exaly